SGD Pharma is pleased to announce the publication of its 2025 Sustainability Report, highlighting the progress achieved across environmental, social and governance (ESG) priorities.

The report reflects the collective efforts of our teams worldwide and outlines key milestones in our journey towards a more sustainable and responsible pharmaceutical glass industry.

From international sustainability recognition to responsible sourcing and employee well-being, 2025 marked another important year of progress.

EcoVadis Platinum and CDP Recognition: Key ESG Achievements

One of the highlights of 2025 was SGD Pharma's EcoVadis Platinum medal for the second consecutive year, with a score of 90/100.

This achievement places SGD Pharma among the top 1% of companies assessed globally by EcoVadis.

Our environmental performance was also recognized through CDP ratings:

  • CDP Climate: A
  • CDP Water: B
  • CDP Supplier Engagement: A

These results reflect our continued efforts to strengthen environmental management and transparency across our operations and value chain.

Strengthening Environmental and Safety Standards

In 2025, all SGD Pharma manufacturing sites achieved certification to three international standards:

Another milestone was reached at our Zhanjiang plant, where SGD Pharma became the first glass manufacturer in China to achieve ISO 14021 certification for post-consumer recycled content.

These achievements demonstrate our commitment to improving environmental performance, energy efficiency and workplace safety.

Promoting Responsible Practices Across Our Supply Chain

Our sustainability commitments extend beyond our manufacturing sites to include our suppliers and partners.

In 2025, 100% of critical suppliers signed SGD Pharma's Supplier Code of Conduct, reinforcing shared expectations for responsible business practices.

We also increased the sustainability weighting in supplier evaluations from 10% to 20%, placing greater emphasis on environmental, social and governance criteria in our sourcing decisions.

Supporting Our People and an Inclusive Workplace

People remain central to SGD Pharma's sustainability approach.

In 2025, we revised our Group HR policy to formalize our commitment to providing a safe, fair and inclusive working environment.

Key initiatives include:

  • A commitment to ensuring a living wage for all permanent employees by 2028.
  • The deployment of the French Gender Equality Index methodology across all locations.
  • A strengthened labor relations framework.

These initiatives support our ambition to promote employee well-being, fairness and inclusion throughout the organization.

Looking Ahead: Continuing Our Sustainability Journey

While the achievements highlighted in our 2025 Sustainability Report represent significant progress, our work continues.

SGD Pharma remains committed to raising standards, accelerating its transformation and contributing positively to the pharmaceutical industry and society.

Together, we are building a more sustainable, resilient and responsible company for the benefit of our stakeholders.

Discover our progress and commitments in the full SGD Pharma Sustainability Report 2025.